

Financial news for BIND dated on 2016-04-07: JMP Securities Downgrades Bind Therapeutics to Market Perform

Financial news for BIND dated on 2016-04-07: Cowen & Company Downgrades Bind Therapeutics to Market Perform

Financial news for BIND dated on 2015-11-08: BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents

Financial news for BIND dated on 2015-04-07: Oppenheimer Initiates Coverage on Bind Therapeutics at Outperform, Announces \$14.00 PT

Financial news for BIND dated on 2015-02-04: BIND Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

Financial news for BIND dated on 2014-12-04: Credit Suisse Downgrades BIND Therapeutics to Neutral, Lowers PT to \$10.00

Financial news for BIND dated on 2014-11-06: BIND Therapeutics Announces Joint Research Agreement with Merck

Financial news for BIND dated on 2014-08-07: BIND Therapeutics Reports Q2 EPS of \$(0.51) vs \$(0.60) Est; Revenue of \$2.46M vs \$2.20M Est

Financial news for BIND dated on 2014-06-19: BIND Therapeutics, Roche Collaborate on Discovery of Novel Nanomedicines

Financial news for BIND dated on 2014-05-08: BIND Therapeutics Reports Q1 EPS of \$(0.51) vs \$(0.52) Est; Revenue of \$1.57M vs \$2.46M Est

Financial news for BIND dated on 2014-03-25: Bind Therapeutics Reports Q4 Loss of \$0.50/Share vs Loss of \$0.41/Share Est.

Financial news for BIND dated on 2014-03-03: BIND Therapeutics Names Jeff Hrkach as Chief Technology Officer, Andrew Hirsch as COO

Financial news for BIND dated on 2013-10-15: UPDATE: JMP Securities Initiates Coverage on BIND Therapeutics on Recipe for Significant Value Creation

Financial news for BIND dated on 2013-10-15: UPDATE: Stifel Initiates Coverage on BIND Therapeutics on Positive Outlook

Financial news for BIND dated on 2013-10-15: Bind Therapeutics Initiated at Outperform by JMP, Cowen, at Buy by Stifel Nicolaus

Financial news for BIND dated on 2013-10-15: Credit Suisse Initiates Coverage on Bind Therapeutics with Outperform Rating and \$21 Target

Financial news for BIND dated on 2013-10-04: 13D Filing from Rusnano Shows 9.28% Stake in Bind Therapeutics

Financial news for BIND dated on 2013-09-20: IPO for Bind Therapeutics Opens at \$15, Priced 4.7M Shares at \$15; Initial Range Was for \$14-16/Share

Financial news for BIND dated on 2013-09-20: Waiting on Several IPOs This Morning